In order to identify a commonly deleted region of 13q14 on chromosome 13, we performed fluorescence in situ hybridization (FISH) on 17 patients with myeloid malignancies and 12 patients with lymphoid leukemia/lymphoma who exhibited either deletion or translocation at 13q14. Three cosmid probes (RB, D13S319 and D13S25) hybridizing to sequences on 13q14 were used. Fourteen of the 17 patients with myeloid malignancies (82.4%) exhibited allelic loss at the RB, D13S319 and D13S25 locus, whereas only three of the 12 patients with lymphoid malignancies (25.0%) exhibited loss within these loci. These three patients had chronic lymphocytic leukemia (CLL). Six, two and one of the remaining nine lymphoid leukemia/lymphoma patients had breakpoints centromeric to the RB gene, telomeric to D13S25 and within the D13S319 locus, respectively. A high frequency of allelic loss was found using these probes in patients with myeloid malignancies, compared to in patients with leukemia in the lymphoid origin, except CLL patients. These results indicate that loss of the RB gene itself or a region between RB and D13S319, which includes commonly deleted loci, may play an important role in myeloid leukemogenesis.
Introduction
Deletions of chromosome 13 have been found in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), myelosclerosis with myeloid metaplasia (MMM), polycythemia vera (PV), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) and adult T cell leukemia (ATL), [1] [2] [3] [4] [5] [6] [7] [8] the incidence being 18.4% in MDS/MPD and 8.1% in chronic lymphoproliferative disorders. Among the chromosomal deletions in MDS, loss of band 13q14 has been described. 9 Translocation at 13q14 was also sometimes found in AML and MDS patients. 10 Deletion of the retinoblastoma (RB) gene was found in Ph-negative myeloproliferative disorder and multiple myeloma. [11] [12] [13] Studies on CLL using microsatellite loci and FISH analysis showed common deletions at either D13S319 or D13S25. [14] [15] [16] [17] [18] [19] [20] [21] D13S319 is located at least 530 kb distal to the RB gene. 19 The physical distance between D13S319 and D13S25 seems to be more than 100 kb. 21 However, the relationship between deletions of long arm of chromosome 13 (13q) and loss of the RB, D13S319, and D13S25 locus is not clear in other hematological diseases. We found a commonly deleted region at 13q14 in myeloid malignancies with cytogenetic deletions or translocations.
Sixteen patients with myeloid disorders, one AML cell line (OHN-GM) 22 and 12 patients with lymphoid disorders who had chromosome aberrations at band 13q14 were investigated in the present study. Clinical diagnoses and the karyotypes are shown in Table 1a and b. Forty-four AML patients who did not have deletion of 13q or monosomy 13 at diagnosis also underwent FISH analysis in the RB gene as a control study.
Chromosome analysis
Cells from bone marrow, peripheral blood or lymph nodes were prepared for G-banding analysis. 23 Chromosome identification and karyotyping were performed as described by ISCN (1995) . 24 
Fluorescence in situ hybridization (FISH)
Bone marrow cell suspensions in Carnoy's fixative, which had been stored at −20°C after cytogenetic analysis were studied for FISH analysis, essentially as described previously. 25, 26 Cells in metaphase were hybridized with a mixture of a biotinylated RB gene cosmid probe (Oncor Science, Gaithersburg, MD, USA) and a whole painting probe of chromosome 13(WCP13) (Vysis, Downers Grove, IL, USA) or with an RB gene probe alone. D13S319 and D13S25 cosmid probes (both from Vysis) were applied to each slide, followed by incubation of the slides at 37°C for 48-72 h in a humidified chamber. After the hybridization, the slides were washed with 50% formamide at 45°C for 5 min and with 2 × SSC at 37°C for 10 min. The RB probe was detected with fluorescein isothiocyanate (FITC)-conjugated avidin (Oncor Science) and the signal was amplified with anti-avidin-FITC (Oncor Science) producing a green signal. The WCP13 probe was detected directly as a red signal without secondary hybridization or amplification. The D13S319 and D13S25 probes were detected as red signals directly without secondary hybridization or amplification. The samples were counterstained with 4Ј,6-diamidine 2Ј-phenylindole dihydrochloride (DAPI) (Boehringer, Mannheim, Germany). The hybridization signals were evaluated in cells in metaphase as well as in 200 interphase nuclei under a fluorescence microscope (Olympus, Tokyo, Japan) using appropriate absorption and excitation filters. 
PCR-SSCP analysis
Six of the 29 patients whose stored DNA samples were available were tested for RB gene mutations using PCR-SSCP, as described previously. 27 PCR was performed using 10 primers covering the five exons of the RB gene (exons 12, 13, 14, 15, and 16), which code for amino acids from positions 393 to 572. The primer sets were reported previously. 28 The reaction mixture contained 2 l DNA, 50 m of each dNTP, 0.25 m KCl, 0.2 units of Taq polymerase, and 0.1 l of ␣ 32 P-dCTP (3000 Ci/mmol, 10 mCi/ml; 1 Ci = 37 GBq) in a volume of 10 l. The mixture was subjected to 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 0.5 min, and extension at 72°C for 2 min, followed by a single 10-min extension step in a Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT, USA). The product of the reaction was initially examined by agarose gel electrophoresis and ethidium bromide staining. The reaction solution was heated at 80°C for 5 min to denature the DNA. It was then applied (2 l per lane) to a 5% nondenaturing acrylamide gel (49:1 ratio of acrylamide to methyl bisacrylamide), containing 90 mm Tris-borate (pH 8.3) and 2 mm EDTA. Electrophoresis was carried out at 4°C and 17°C at 30 W constant power. After electrophoresis, the gel was transferred to Whatman 3MM paper and dried on a vacuum slab gel dryer. Autoradiography using Fuji medical X-ray film at −70°C with an intensifying screen for 12-48 h allowed detection of the PCR product.
Results
Nine out of 10 patients (90%) of myeloid malignancies (patients 1-10) with chromosome 13 deletion exhibited allelic loss between the RB gene and the D13S25 locus as determined by FISH analysis (Figure 1, Table 1a ). Patient 10 did not exhibit allelic loss. Five of seven patients with myeloid malignancies (71.4%) exhibiting chromosome translocation also had allelic loss in the same locus (patients 11-13) or loss of the RB gene only (patients 14 and 15). In total, 14 out of the 17 patients with myeloid malignancies (82.4%) exhibited allelic loss at either locus of the RB gene, D13S319, and D13S25, or loss of the RB gene only. On the other hand, only three CLL patients (patients 18-20) (25.0%) exhibited allelic loss in these loci among 12 patients with lymphoid malignancies exhibiting deletion (patients [18] [19] [20] [21] [22] or translocation (patients [23] [24] [25] [26] [27] [28] [29] (Figure 1, Table 1b ). Of the three, two exhibited allelic loss at both the RB gene and the D13S319 loci and one in all loci of the RB gene, D13S319 and D13S25. PCR-SSCP analysis was performed for six patients (patients 3, 4, 8, 9, 12, and 13) exhibiting loss of either locus at the RB gene, D13S319 or D13S25. The results showed no patients with alterations of exons 12-16 of the RB gene.
Discussion
The results of this study showed that regions with the RB gene, D13S319 or D13S25 locus frequently showed allelic loss in patients with myeloid malignancies (82.4%) exhibiting chromosomal deletion or translocation at 13q14. It is expected that most patients with myeloid malignancies (such as patients 1-9 and patients 11-13) would often have loss of heterozygosity (LOH) with large deletion from 13q12 to 13q14 and that some patients (such as patients 14 and 15) would only have loss of the RB gene. The RB gene locus was commonly deleted among these 14 patients with myeloid phenotype. These results indicated that loss of the RB gene might play an important role in the pathogenesis of myeloid malignancies with deletion or translocation at 13q14. A recently published FISH study showed findings similar to ours, in which analysis of 20 and eight myeloid malignancies with deletion or translocation at 13q14 commonly had deleted regions involving the RB gene. 29, 30 Since probes centromeric to the RB gene were not tested in the present study, we could not confirm that the RB gene is the only loss in myeloid malignancies. However, only three CLL patients had loss of the RB locus among 12 patients with lymphoid malignancies, exhibiting chromosomal deletion or translocation at 13q14. Consequently, the role of the RB gene in lymphoid patients with 13q14 abnormalities except CLL patients was actually expected to be different from that in the myeloid patients. One AML patient (patient 10) who had deletion of chromosome 13 at 13q14 to 13q22, did not have any loss of RB, D13S319 or D13S25 locus, although it was expected that deletion of chromosome 13q would have occurred at the region distal to the D13S25 locus. This patient was an atomic bomb survivor and had been exposed to 5.18 Gy of radiation in Hiroshima. She was also a secondary leukemia patient who had been suffering from breast cancer for the past 5 years. The karyotypes of AML patients developed from heavily exposed atomic bomb survivors had different features, which were extremely complex and did not have any specific type of chromosome aberrations, such as 8;21, 15;17 and 11q23 translocations (manuscript in preparation). However, it has not yet been confirmed whether the deletion that occurred at a different chromosomal region in this patient was due to atomic bomb radiation or to chemotherapy.
Patients 18, 19 and 20 with CLL had deletion of both RB and D13S319, but retained D13S25. Our previous FISH study showed that 28.6% of Japanese CLL patients had deletion of the RB gene. 25 Liu et al 18 reported 44%, 25%, 28% and 6.7% loss of heterozygosity at the RB, D13S319 or D13S25 loci in CLL, B-NHL, B-ALL and T-ALL patients, respectively, by Southern blot analysis. A previous report suggested that CLL patients with 13q deletion usually carried one intact RB gene. 16 This report also suggested that the D13S319 locus has a high incidence of homozygous deletion. 18 However, our FISH analysis did not confirm this homozygous deletion. A prolymphocytic leukemia (PLL) patient (patient 23) with t(4;13) had a breakpoint within the D13S319 locus. These studies, together with the findings of the present study, suggest that two distinct mechanisms may exist, ie the RB gene itself or gene(s) close to the RB gene may be the cause of deletion of 13q in myeloid leukemia, whereas another gene or a gene near D13S319 might play a role in CLL.
In the present study, six lymphoid leukemia/lymphoma patients showed breakpoints outside the region from RB to D13S25, of which four patients with T cell phenotypes had breakpoints centromeric to the RB gene. Therefore, previously unidentified oncogene(s) related to T cell leukemia/lymphoma might be located around this region. The BRCA2 gene mapping at 13q12 was proven to be deleted at a high frequency in B-CLL patients, 31 although a discrepant result was published. 32 The RMS gene, which is associated with rhabdomyosarcoma, is located distal to the RB gene. 33 No RB gene expression was found in some patients with AML, irrespective of the presence or absence of the RB gene locus in our separate experiment. Of the 29 patients whose metaphase/interphase cells were analyzed by the FISH method, five were examined for RB gene expression by Western blot analysis. The five patients examined consisted of two (patients 4 and 14) who exhibited loss of the RB gene, three (patients 16, 17 and 27) who did not exhibit loss of the RB gene. Four of the five patients did not exhibit RB gene expression (patients 4, 14, 16 and 17). The remaining patient (patient 27) with duplication of 13q14 exhibited RB gene expression, although the level was lower than that of the control (K562 cell line). In a large-scale study on leukemia and lymphomas, 27% of AML patients did not express the RB protein. 34 Another study showed that 25% of AML patients (eight of 32 patients) and 50% of CMLbc patients (four of eight patients) had no detectable RB gene expression. 35 Twenty of 106 AML patients showed no expression of the RB protein as determined by Western blot analysis. 36 In contrast, another study showed that only one of 12 ALL patients and two CLL patients had low levels of RB protein expression. 35 Similarly, none of 57 AML/CMLbc patients exhibited gross alteration of the RB gene. 36 Southern blot analysis did not detect gene rearrangement in 86 patients. 37 These results indicate that other mechanisms, such as post-transcriptional or post-translational modification without point mutation or gene rearrangement on the RB gene, might be involved in the inactivation of the RB gene in most myeloid leukemia patients with 13q14 abnormalities. [37] [38] [39] [40] The RB gene encodes a nuclear protein that plays an important role in the cell cycle. The product of the RB gene is believed to function as a negative regulator of cell growth. The function of the RB gene is regulated by several cell cycle-dependent reactions, such as phosphorylation/ dephosphorylation. The RB protein may exert its growth-suppressing activity by regulating the transcription of several growth related genes. 41 Low levels of expression of the RB protein as a result of the loss of the RB gene on one allele might de-regulate the cell cycle in myeloid leukemia cells and finally lead to progression to the aggression stage and to poor prognosis. 42 Abnormal expression of the RB gene due to inactivation of the RB allele has been implicated in the development of retinoblastoma. 43 Patients with hereditary diseases were confirmed to have one inactivated allele of the RB gene due to a germ-line mutation, gene rearrangement or deletion. 44 A somatic event inactivating the remaining normal allele leads to complete loss of the RB gene function. We expected that leukemia patients with loss of the RB gene might have mutations of the remaining RB allele. However, our PCR-SSCP analysis in six patients with myeloid disorders showed no detectable alteration of the five exons (exons 12 to 16) of the RB gene encoding pocket A in RB protein, where the E1A binding domain was involved. 45, 46 This cannot rule out the possibility of a mutation occurring on the remaining allele of the RB gene in patients with allelic loss of 13q. The exons encoding pockets B and C terminal of the RB protein and the promoter region, all of which play important roles in RB functions, were not included.
